ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Advocacy
  • Anal cancer
  • Artificial intelligence (AI)
  • Bladder cancer
  • Brain cancer
  • Breast cancer
  • Colorectal cancer
  • ComboMATCH
  • Esophagus cancer
  • Gallbladder cancer
  • Head and neck cancer
  • Health equity
  • Immunotherapy
  • In memory
  • Kidney cancer
  • Leukemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Melanoma
  • Myelodysplastic syndrome
  • Myeloma
  • NCI-MATCH
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penis cancer
  • Personalized treatment
  • Policy
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Real-world data/evidence
  • Research results
  • Sarcoma
  • Screening for cancer
  • Side effects
  • Survivorship
  • Targeted therapy
  • Upper tract urothelial cancer
  • Young adults
December 15, 2021
Research dictionary entry
December 15, 2021
Categories
  • Trial Results

Trial Results: Blood cancers are the focus of recent ECOG-ACRIN research

Summaries of leukemia, lymphoma, and myeloma research results
Do you like it?
0 Read more
October 14, 2019
October 14, 2019
Categories
  • Trial Results

Trial Results: With E1912, there is a new standard of care for the initial treatment of patients with chronic lymphocytic leukemia

The combination of ibrutinib plus rituximab was superior to standard treatment for CLL patients age 70 and younger.
Do you like it?
0 Read more
Prev page
123

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2026 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc